Trial · NCT00630565
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
NCT00630565, Phase 2, Phase 3, Terminated, Masonic Cancer Center, University of Minnesota; results first posted 2024-01-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia. Trials, record NCT00630565. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00630565
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
- NCT number
- NCT00630565
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 12 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Leukemia
- Interventions
sargramostim, busulfan, cyclophosphamide, dexamethasone, etoposide, bone marrow transplantation, hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
- First posted
- 2008-03-07
- Last updated
- 2024-01-29
- Results first posted
- 2024-01-29
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Engraftment | 30 Days Post Transplant | Percentage of Participants with Engraftment measured by myeloid, platelet, and erythroid recovery |
| Secondary | Percentage of Participants With Disease Response | 2 years Post Transplant | Disease evaluation will be completed approximately 100 days after stem cell infusion and every 6 months, 1 year, and until 2 years after infusion. |
| Secondary | Treatment Failure | 2 years Post Transplant | Percentage of participants experiencing treatment failure. |
| Secondary | Percent of Patients With Various Late Effects | 2 years Post Transplant | Description: (e.g., thyroid function abnormalities - T4, TSH, gonadal abnormalities, cataracts, pulmonary dysfunctions, growth and development abnormalities, and second malignant neoplasms) |
| Secondary | Disease-free Survival | 2 years Post Transplant | Disease-free survival 2 years Post Transplant |
| Secondary | Percentage of Patients With Adequate Cells Collected | Pre-Transplant | The proportion of primed patients with adequate number of cells collected will be calculated. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Engraftment | 30 Days Post Transplant | Participants of participants | NUMBER | |
| SECONDARY | Percentage of Participants With Disease Response | 2 years Post Transplant | Percentage of participants | NUMBER | |
| SECONDARY | Treatment Failure | 2 years Post Transplant | Percentage of participants | NUMBER | |
| SECONDARY | Percent of Patients With Various Late Effects | 2 years Post Transplant | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Disease-free Survival | 2 years Post Transplant | Percentage of participants with DFS | NUMBER | |
| SECONDARY | Percentage of Patients With Adequate Cells Collected | Pre-Transplant | Percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Engraftment | Bone Marrow Transplant (2-70 Years Old) | 100 | 95% Confidence Interval 76 to 100 | Participants of participants | |
| Percentage of Participants With Disease Response | Bone Marrow Transplant (2-70 Years Old) | 83 | 95% Confidence Interval 46 to 95 | Percentage of participants | |
| Treatment Failure | Bone Marrow Transplant (2-70 Years Old) | 25 | Percentage of participants | ||
| Percent of Patients With Various Late Effects | Bone Marrow Transplant (2-70 Years Old) | 0 | Participants | ||
| Disease-free Survival | Bone Marrow Transplant (2-70 Years Old) | 73 | 95% Confidence Interval 38 to 91 | Percentage of participants with DFS | |
| Percentage of Patients With Adequate Cells Collected | Bone Marrow Transplant (2-70 Years Old) | 75 | 95% Confidence Interval 47 to 91 | Percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bone Marrow Transplant (2-70 Years Old) | 12 | |
| Overall Study | STARTED | Bone Marrow Transplant (Less and 2 Years Old) | 0 | |
| Overall Study | COMPLETED | Bone Marrow Transplant (2-70 Years Old) | 12 | |
| Overall Study | COMPLETED | Bone Marrow Transplant (Less and 2 Years Old) | 0 | |
| Overall Study | NOT COMPLETED | Bone Marrow Transplant (2-70 Years Old) | 0 | |
| Overall Study | NOT COMPLETED | Bone Marrow Transplant (Less and 2 Years Old) | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Relapse | Blood and lymphatic system disorders | Bone Marrow Transplant (2-70 Years Old) | 1 | 12 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bone Marrow Transplant (2-70 Years Old) | 0 | 12 |
| Total, other adverse events | Bone Marrow Transplant (2-70 Years Old) | 0 | 12 |
| Total, serious adverse events | Bone Marrow Transplant (2-70 Years Old) | 1 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00630565
GET https://conductscience.org/api/trials/v1/NCT00630565/registered